These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35855578)

  • 21. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.
    Meeks JJ; Taylor JM; Matsushita K; Herr HW; Donat SM; Bochner BH; Dalbagni G
    BJU Int; 2013 Jun; 111(8):E325-30. PubMed ID: 23384236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
    Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M;
    Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncologic Outcomes of cT1 and cT2 Micropapillary Variant Compared with cT1 and cT2 Conventional Urothelial Carcinoma Treated with Radical Cystectomy.
    Ginsburg KB; Schober JP; Bukavina L; Murray N; Chandra AA; Chen DYT; Greenberg RE; Viterbo R; Uzzo RG; Smaldone MC; Kutikov A; Correa AF
    Urol Pract; 2022 Sep; 9(5):396-404. PubMed ID: 37145732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.
    Kamat AM; Dinney CP; Gee JR; Grossman HB; Siefker-Radtke AO; Tamboli P; Detry MA; Robinson TL; Pisters LL
    Cancer; 2007 Jul; 110(1):62-7. PubMed ID: 17542024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmacytoid urothelial carcinoma of the urinary bladder: a clinical pathological study and literature review.
    Wang Z; Lu T; Du L; Hu Z; Zhuang Q; Li Y; Wang CY; Zhu H; Ye Z
    Int J Clin Exp Pathol; 2012; 5(6):601-8. PubMed ID: 22949945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
    Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
    J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
    Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What Is the Significance of Variant Histology in Urothelial Carcinoma?
    Lobo N; Shariat SF; Guo CC; Fernandez MI; Kassouf W; Choudhury A; Gao J; Williams SB; Galsky MD; Taylor JA; Roupret M; Kamat AM
    Eur Urol Focus; 2020 Jul; 6(4):653-663. PubMed ID: 31530497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer.
    Motterle G; Andrews JR; Morlacco A; Karnes RJ
    Eur Urol Focus; 2020 Jul; 6(4):642-649. PubMed ID: 31708469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Achkar T; Parikh RA
    Urol Clin North Am; 2018 May; 45(2):257-266. PubMed ID: 29650141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.
    Meyer A; Ghandour R; Bergman A; Castaneda C; Wosnitzer M; Hruby G; Benson M; McKiernan J
    J Urol; 2014 Sep; 192(3):696-701. PubMed ID: 24657802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Tabayoyong W; Li R; Gao J; Kamat A
    Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The prognostic value of adjuvant and neoadjuvant chemotherapy in total cystectomy for locally advanced bladder cancer].
    Habuchi T; Kakehi Y; Terachi T; Ogawa O; Yoshida O
    Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):809-17. PubMed ID: 10565159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What About Variant Histologies in Bladder Cancer?
    Day E; Gavira J; Tapia JC; Anguera G; Maroto P
    Eur Urol Focus; 2024 Mar; 10(2):227-230. PubMed ID: 38849276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.